Clinical Trial Update: Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study [Phase 2]

View source ↗

Summary

A multicenter Phase II study evaluating platinum-based chemotherapy with bevacizumab and durvalumab, plus salvage SBRT, in stage IV EGFR-mutant NSCLC after fail…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Durvalumab (durvalumab)
• Platinum-based chemotherapy (platinum-based chemotherapy)
• SBRT (stereotactic body radiotherapy)

Snippet

Sponsor: Shanghai Cancer Hospital, China | Conditions: Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT | Phase 2 | Status: UNKNOWN